Spectrum Pharmaceuticals, Inc.  

(Public, NASDAQ:SPPI)   Watch this stock  
Find more results for SPPI
4.05
+0.02 (0.50%)
Real-time:   10:05AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.95 - 4.07
52 week 3.21 - 7.74
Open 3.97
Vol / Avg. 48,445.00/850,655.00
Mkt cap 328.71M
P/E     -
Div/yield     -
EPS -0.78
Shares 80.56M
Beta 1.15
Inst. own 72%
Nov 14, 2016
Q3 2016 Spectrum Pharmaceuticals Inc Earnings Release
Sep 12, 2016
Spectrum Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Sep 9, 2016
Spectrum Pharmaceuticals Inc at Biocentury NewsMakers in the Biotech Industry
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -52.27% -31.24%
Operating margin -47.90% -25.06%
EBITD margin - -1.05%
Return on average assets -15.94% -11.17%
Return on average equity -28.77% -21.74%
Employees 212 -
CDP Score - -

Address

11500 S Eastern Ave Ste 240
HENDERSON, NV 89052-5576
United States - Map
+1-702-8356300 (Phone)
+1-702-2607405 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin's lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.

Officers and directors

Rajesh C. Shrotriya M.D. Chairman of the Board, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Joseph W. Turgeon President, Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Kurt A. Gustafson Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Luigi Lenaz M.D. Lead Independent Director
Age: 74
Bio & Compensation  - Reuters
Gilles R. Gagnon Director
Age: 61
Bio & Compensation  - Reuters
Raymond Wayne Cohen Independent Director
Age: 56
Bio & Compensation  - Reuters
Stuart M. Krassner Independent Director
Age: 79
Bio & Compensation  - Reuters
Anthony E. Maida III, Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters